Vifor Pharma
Flughofstrasse 61
Glattbrugg
CH-8152
Tel: 41-58-8518000
Fax: 41-58-8518001
Website: http://www.viforpharma.com/
99 articles with Vifor Pharma
-
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
12/14/2022
Vifor Pharma AG announced that the Commercial Court St. Gallen has cancelled all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each.
-
Approval of extension of exemptions from SIX disclosure and publicity obligations
10/20/2022
Vifor Pharma AG announced that by decision dated October 19, 2022, SIX Exchange Regulation AG has approved an extension of the various exemptions from certain disclosure and publicity obligations granted by SER to Vifor Pharma AG previously.
-
Approval of delisting of Vifor Pharma AG's registered shares
10/12/2022
Vifor Pharma AG announced that Vifor has received approval for the delisting of the totality of Vifor's registered shares.
-
Finalization of Vifor Pharma acquisition
8/2/2022
CSL Limited is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma AG announced on 14 December 2021.
-
Update on the timeline for Vifor Pharma tender offer
5/12/2022
CSL Limited yesterday announced an update regarding the Vifor Pharma AG acquisition.
-
94th Vifor Pharma Group Annual General Meeting
4/26/2022
At 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.
-
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
4/4/2022
Vifor Pharma announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve long-term potassium control, reduced the risk of recurrent hyperkalemia and prolonged optimized and guideline recommended renin-angiotensin aldosterone system inhibitor therapy.
-
Publication of definitive end result for Vifor Pharma tender offer
3/28/2022
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the definitive notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
-
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
3/23/2022
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
-
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
3/8/2022
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd.
-
Vifor Pharma reports sustained growth in 2021
2/17/2022
Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject® / Injectafer® sales from the second quarter 2021 on, and sustained by positive momentum in the second half of 2021.
-
Vifor Pharma appoints two new members to the Executive Committee
2/2/2022
Vifor Pharma Group announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr. Oliver P. Kronenberg as members of the Vifor Pharma Executive Committee, effective 1 February 2022.
-
CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma
2/1/2022
CordenPharma announced the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. in Switzerland, and Corden Pharma Lisbon S.A. in Portugal.
-
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
1/18/2022
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd., a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therapies, as indicated in the pre-announcement of the public tender offer published by CSL Limited on 14 December 2021.
-
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
12/21/2021
Vifor Pharma announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor therapy.
-
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
12/16/2021
Vifor Pharma Group today announced the divestment of its finished drug product manufacturing business to CordenPharma.
-
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
12/14/2021
Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion.
-
If successfully finalized, the transaction will give CSL access to Vifor’s pipeline of treatments for iron deficiency, kidney and cardio-renal diseases.
-
The deal, which could be worth as much as $12 billion USD, was also confirmed by CSL speaking to Reuters Monday morning.
-
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
12/10/2021
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult patients with sickle cell disease.